Tactile Medical projects $360M-$366M 2026 revenue as airway clearance ordering normalizes in Q4 (NASDAQ:TCMD)
TCMD Q2 2026 earnings call recap: raised revenue guidance to $360â$366M, lymphedema strength, AffloVest inventory reset, Medicare prior auth impactâread...
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
TCMD Q2 2026 earnings call recap: raised revenue guidance to $360â$366M, lymphedema strength, AffloVest inventory reset, Medicare prior auth impactâread...
Tactile Medical projects $360M-$366M 2026 revenue as airway clearance ordering normalizes in Q4 (NASDAQ:TCMD) | Seeking Alpha
Earnings Call Insights: Tactile Systems Technology (TCMD) Q2 2026
Management view
"We delivered another strong quarter of execution in Q2, highlighted by continued strength in our lymphedema business and meaningful profitability expansion." (CEO, President & Director Sheri Dodd)
"Based on
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
What are the main drivers of Tactile Systems Technology's updated 2026 revenue guidance?
Lymphedema business strength and launch of new distribution agreement with ElastiMed are boosting revenue, while airway clearance segment faces temporary inventory disruptions.
How are Medicare prior authorization and inventory management affecting TCMD's lymphedema and airway clearance businesses?
Medicare prior authorization has caused near-term moderation in lymphedema order volumes, and inventory management dynamics among DME partners have led to a temporary decline in airway clearance revenue, expected to normalize later in the year.
What is the impact of AffloVest inventory dynamics and product launches on TCMD's financial outlook?
AffloVest ordering dropped due to partners managing inventory post-next-gen launch; management expects this to continue through Q3 but normalize in Q4, with the potential for resumed growth once inventory levels rebalance.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
IHeartMedia Reaffirms $800M EBITDA Target, Q3 Guidance of $180M-$220M Highlights Ad Market Resilience
IHeartMedia maintains its full-year adjusted EBITDA target of $800 million and free cash flow of $200 million, with Q3 guidance of $180-$220 million. Political advertising supports broadcast, while digital growth slows and cost control becomes key.
Webtoon Q3 Revenue Guidance Hits $358-368M, Q4 Target Set for Double-Digit Growth: What US Investors Need to Know
Webtoon Entertainment projects Q3 2024 revenue of $358-368 million and targets double-digit growth in Q4, signaling confidence in its business model. This article analyzes growth drivers, market context, and potential risks for US investors.
Definitive Healthcare Raises 2026 Revenue Guidance, Turbo Product to Reach General Availability by Year-End
Definitive Healthcare lifts its 2026 revenue outlook to $220-$222 million and plans to launch Turbo, its AI-driven data platform, to all customers by year-end, signaling strong growth in the healthcare data sector.
Rapid7's 2026 Exit Signal: Deep Dive into 20% Margin Target and 12% Workforce Restructuring
Rapid7 announces 2026 exit plan with ~20% non-GAAP operating margin target and 12% workforce restructuring. This analysis explores strategic intent, financial feasibility, and industry context for investors.
